Researchers at Mass General Brigham have identified a rare genetic variant in the RELN gene that protected a man from Alzheimer’s symptoms for nearly three decades. This discovery highlights a specific protein pathway that could be targeted to mimic this natural resistance in others.
TLDR: Scientists identified a rare genetic mutation in the RELN gene that shielded a patient from Alzheimer’s symptoms despite high genetic risk. This breakthrough reveals a new biological pathway for protecting brain health, potentially leading to therapies that mimic this natural resistance to cognitive decline.
Researchers at Mass General Brigham have identified a rare genetic variant that appears to provide significant protection against the symptoms of Alzheimer’s disease. The study, published in Nature Medicine, focuses on a man from a large family in Colombia who carried the Presenilin-1 (PSEN1) E280A mutation. This specific mutation typically guarantees the onset of cognitive impairment by the age of 44 and dementia by 49. However, the subject remained cognitively healthy until his late 60s, defying the expected progression of the disease by nearly thirty years. This case provides a unique window into the biological mechanisms that can delay or prevent neurodegeneration even in the presence of high-risk genetic factors.
The research team, led by Dr. Yakeel Quiroz and Dr. Francisco Lopera, conducted extensive genomic and proteomic analyses to understand this anomaly. They discovered that the patient carried a rare variant in the RELN gene, which encodes the Reelin protein. This protein plays a critical role in brain development and the signaling between neurons throughout a person’s life. While the patient’s brain showed high levels of amyloid-beta plaques—a hallmark of Alzheimer’s—the Reelin variant appeared to protect his entorhinal cortex, a region vital for memory and navigation. This specific localization of protection is significant because the entorhinal cortex is usually one of the first areas to succumb to the disease.
This finding marks the second time a specific genetic variant has been linked to extreme resilience against Alzheimer’s in this specific Colombian kindred. Previously, researchers identified the APOE3 Christchurch variant in a woman who also showed delayed cognitive decline. The discovery of the Reelin variant suggests that there are multiple biological pathways that can be leveraged to prevent the neurodegeneration associated with the disease. The Reelin protein works by binding to the same receptors as the APOE protein, influencing the phosphorylation of tau proteins. Tau proteins are responsible for forming the toxic tangles that eventually kill brain cells, and the Reelin variant seems to inhibit this destructive process.
The study utilized advanced neuroimaging techniques, including Positron Emission Tomography (PET) scans, to visualize the distribution of plaques and tangles in the patient’s brain. Despite the presence of extensive amyloid, the levels of tau tangles were remarkably low in the areas protected by the Reelin variant. This suggests that the genetic mutation effectively decoupled the presence of amyloid from the subsequent spread of tau, which is more closely linked to actual cognitive loss. By maintaining the integrity of the entorhinal cortex, the patient was able to preserve his memory and cognitive function far longer than his peers with the same PSEN1 mutation.
Hospital researchers are now exploring how to translate these genetic insights into clinical treatments. By developing drugs that mimic the effect of the Reelin variant or enhance Reelin signaling, scientists hope to provide similar protection to individuals who do not naturally possess these mutations. This approach represents a shift toward “protective” medicine, focusing on the mechanisms that keep people healthy rather than solely targeting the pathology of the disease. The goal is to create a therapeutic intervention that can bolster the brain’s resilience against the accumulation of toxic proteins.
Future research will involve testing Reelin-based therapies in animal models and eventually in human clinical trials. The team is also searching for other protective variants within the same population, hoping to uncover a broader map of genetic resilience. These efforts could lead to a new generation of Alzheimer’s treatments that bolster the brain’s natural defenses against aging and neurodegeneration. Understanding why some people are naturally resistant to dementia remains one of the most promising frontiers in modern neurology.
Susan Carter serves as a Senior Correspondent for Just Right News, where she leads the network’s comprehensive coverage of Health, Medicine, and Public Policy. With a career dedicated to dissecting the complexities of the American healthcare system, Susan brings a principled perspective to the most pressing debates of the day. Her reporting is characterized by a commitment to individual liberty, fiscal responsibility, and a healthy skepticism of government overreach, making her a vital voice for audiences seeking clarity in an increasingly regulated landscape.
Raised in Minneapolis, Minnesota, Susan’s professional outlook is deeply informed by the values of the American heartland. Growing up in the Twin Cities, she witnessed firsthand the importance of community-driven solutions and the resilience of the individual. This Midwestern foundation instilled in her a firm belief that the best answers to public policy challenges often come from local innovation and personal responsibility rather than top-down federal mandates. Her background allows her to translate complex legislative jargon into stories that resonate with families who value common sense and local autonomy.
Now based in Baltimore, Maryland, Susan operates from a unique vantage point at the intersection of medical innovation and urban policy. Living and working in a city renowned for its world-class medical institutions and significant public health challenges, she has a front-row seat to the realities of the modern healthcare landscape. Her proximity to these hubs of research and policy allows her to scrutinize how government intervention affects the quality of care and the freedom of medical professionals. In Baltimore, she sees the tangible results of policy decisions, using the city as a lens through which to examine the broader national health debate and the impact of federal spending on local communities.
As the lead for the acclaimed feature series “The Cost of Care,” Susan dives deep into the economic realities facing patients and providers alike. Her work focuses on the necessity of price transparency, the benefits of market competition, and the preservation of the sacred doctor-patient relationship. She is a staunch advocate for the idea that a well-informed public is the best defense against bureaucratic inefficiency. Through this series, she has exposed the hidden drivers of rising medical expenses, always seeking to empower the individual consumer over the massive institution.
Susan’s reporting on public policy is characterized by a commitment to rigorous inquiry and a focus on constitutional limits. Whether she is analyzing new pharmaceutical regulations, investigating the impact of federal health mandates, or exploring the future of medical technology, her goal remains the same: to provide Just Right News audiences with the facts they need to navigate a complex world. By blending her Midwestern sensibilities with the insights gained from her base in Maryland, Susan Carter has become a trusted authority for those who believe that personal freedom and public health are inextricably linked. Her work continues to challenge the status quo, advocating for a system that respects the taxpayer and prioritizes the patient.